> top > docs > PMC:7784830 > spans > 22158-24720 > annotations

PMC:7784830 / 22158-24720 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
391 54-62 Disease denotes COVID-19 MESH:C000657245
398 748-752 Species denotes nCoV Tax:2697049
399 1054-1065 Species denotes coronavirus Tax:11118
400 1631-1643 Species denotes corona virus Tax:11118
401 1708-1722 Species denotes horsepox virus Tax:397342
402 1948-1980 Disease denotes Middle East Respiratory Syndrome MESH:D018352
403 1982-1986 Disease denotes MERS MESH:D018352

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T7 2213-2221 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T170 0-8 Sentence denotes Table 5.
T171 10-63 Sentence denotes Antiviral vaccines in pipeline for treating COVID-19.
T172 64-137 Sentence denotes Name of the player Details of antiviral vaccines under development Ref.
T173 138-312 Sentence denotes Migal Galilee Research Institute, Israel Developing an oral (mucosal) vaccine, wherein the viral antigen is delivered via mucosa tissues by self-activated endocytosis [104]
T174 313-446 Sentence denotes Entos Pharmaceuticals Fusogenix – DNA vaccine is being developed based on its patent protected platform, proteo-lipid vehicle (PLV).
T175 447-528 Sentence denotes It uses a new mechanism for delivering genetic material into the cells [105,106]
T176 529-613 Sentence denotes Vaxart Inc Oral recombinant vaccine in tablet formulation using its VAAST platform.
T177 614-698 Sentence denotes It has protected its vaccine tablet formulation by US patent applications [107–109]
T178 699-829 Sentence denotes University of Oxford – Jenner Institute ChAD0X1 nCoV-19 – prepared from cold virus (weakened) – initiated Phase III trials [110]
T179 830-945 Sentence denotes Altimmune AdCOVID – vaccine delivered via intranasal route platform technologies NasoVAX and NasoShield [111,112]
T180 946-998 Sentence denotes Medicago Developing a vaccine and also an antibody.
T181 999-1066 Sentence denotes It was successful in producing virus like particles of coronavirus.
T182 1067-1140 Sentence denotes It is developing antibodies in collaboration with Laval University [113]
T183 1141-1265 Sentence denotes Inovio Pharmaceuticals INO-4800 – vaccine that is developed in collaboration with Beijing Advaccinee Biotechnology Company.
T184 1266-1421 Sentence denotes It is proposing to deliver the vaccine using the device called as CELLECTRA® which works by creating a pulse for transferring the plasmids across the cell.
T185 1422-1511 Sentence denotes It is also developing INO 4700 in collaboration with GeneOne Life Sciences company [114]
T186 1512-1584 Sentence denotes Moderna mRN 1273 – recently received fast track designation from USFDA.
T187 1585-1650 Sentence denotes It vaccine basically targets spike protein of corona virus [115]
T188 1651-1740 Sentence denotes Tonix Pharmaceuticals TNX-1800 – developed based on its horsepox virus vaccine platform.
T189 1741-1804 Sentence denotes It has filed a provisional patent application with USPTO [116]
T190 1805-1933 Sentence denotes Clover Biopharmaceuticals Subunit vaccine developed using trimeric spike protein developed using its patented technology [117]
T191 1934-2066 Sentence denotes Novavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology.
T192 2067-2201 Sentence denotes The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations [118–121]
T193 2202-2402 Sentence denotes Predictive oncology (PO) Introduced artificial intelligence for development of a vaccine using Inventa Biotech’s HSCTM technology which deals with chromatographic system of high throughput screening.